There are currently 54 active clinical trials seeking participants for Sarcoma research studies. The states with the highest number of trials for Sarcoma participants are California, New York, Ohio and Texas.
Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological Studies
NCT01109394
Recruiting
Background: - Laboratory investigators who are studying common childhood cancers are interested in developing a tissue repository to collect and store blood, serum, tissue, urine, or tumors of children who have cancer or adults who have common childhood cancers. To develop this repository, additional samples will be collected from children and adults who have been diagnosed with common childhood cancers such as leukemia and tumors of the central nervous system. Objectives: - To collect and st... Read More
Gender:
ALL
Ages:
4 weeks and above
Trial Updated:
03/14/2025
Locations: Children's National Medical Center, Washington, District of Columbia +4 locations
Conditions: Sarcoma, Endocrine Tumors, Neuroblastoma, Retinoblastoma, Renal Cancer
Register for Updates
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
NCT02390752
Recruiting
Background: - Some people with cancer have solid tumors. Others have refractory leukemia. This may not go away after treatment. Researchers want to see if a drug called TURALIO(R) can shrink tumors or stop them from growing. Objectives: - To find the highest safe dose and side effects of TURALIO(R). To see if it helps treat certain types of cancer. Eligibility: - People ages 3-35 with a solid tumor or leukemia that has returned or not responded to cancer therapies. Design: * Participants... Read More
Gender:
ALL
Ages:
Between 3 years and 35 years
Trial Updated:
03/14/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Neurofibroma, Plexiform, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Sarcoma, Leukemia, Promyelocytic, Acute
Register for Updates
GRID Therapy for Extremity Soft Tissue Sarcoma
NCT06073067
Recruiting
Patients with extremity soft tissue sarcoma (STS) are at high risk of recurrence. Pre-operative radiotherapy is used to increase the safe removal of tumors and improve local control in these patients. Increasing the preoperative radiotherapy dose with standard techniques might lead to normal tissue toxicity and postoperative wound complications. GRID radiation therapy is a technique that may increases radiation dose with minimal added toxicity. It is hypothesized that GRID radiation dose will i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: University of North Carolina at Chapel Hill, Department of Radiation Oncology, Chapel Hill, North Carolina
Conditions: Sarcoma
Register for Updates
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients with Solid Tumors
NCT06789172
Recruiting
The purpose of this study is to investigate the study drug, OKN4395, administered alone and in combination with pembrolizumab. The overall objectives of this study are to determine the safety and tolerability (degree to which side effects of a drug can be tolerated) of OKN4395 alone and in combination with pembrolizumab, OKN4395 and metabolites (broken-down substances) of OKN4395 levels in the blood, and antitumor activity of OKN4395 alone and in combination with pembrolizumab. This study will... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Precision NextGen Oncology and Research Center, Beverly Hills, California +2 locations
Conditions: Solid Tumours, Sarcoma, Squamous NSCLC, Malignant Mesothelioma, HNSCC, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Register for Updates
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT05334069
Recruiting
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.
Gender:
ALL
Ages:
Between 40 years and 75 years
Trial Updated:
03/06/2025
Locations: Anchorage Associates in Radiation Medicine, Anchorage, Alaska +687 locations
Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Ann Arbor Stage I Lymphoma, Ann Arbor Stage II Lymphoma, Ann Arbor Stage III Lymphoma, Ann Arbor Stage IV Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Gastroesophageal Junction Adenocarcinoma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Invasive Breast Carcinoma, Kidney Carcinoma, Malignant Hepatobiliary Neoplasm, Malignant Solid Neoplasm, Melanoma, Muscle-Invasive Bladder Carcinoma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma, RISS Stage III Plasma Cell Myeloma, Sarcoma, Stage I Bladder Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage I Colorectal Cancer AJCC v6 and v7, Stage I Esophageal Cancer AJCC V7, Stage I Gastric Cancer AJCC V7, Stage I Lung Cancer AJCC v7, Stage I Ovarian Cancer AJCC v6 and v7, Stage I Pancreatic Cancer AJCC v6 and v7, Stage I Prostate Cancer AJCC v7, Stage I Uterine Corpus Cancer AJCC v7, Stage II Bladder Cancer AJCC v6 and v7, Stage II Breast Cancer AJCC v6 and v7, Stage II Colorectal Cancer AJCC v7, Stage II Esophageal Cancer AJCC v7, Stage II Gastric Cancer AJCC v7, Stage II Lung Cancer AJCC v7, Stage II Ovarian Cancer AJCC v6 and v7, Stage II Pancreatic Cancer AJCC v6 and v7, Stage II Prostate Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7, Stage III Bladder Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage III Colorectal Cancer AJCC v7, Stage III Esophageal Cancer AJCC v7, Stage III Gastric Cancer AJCC v7, Stage III Lung Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage III Prostate Cancer AJCC v7, Stage III Uterine Corpus Cancer AJCC v7, Stage IV Bladder Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Colorectal Cancer AJCC v7, Stage IV Esophageal Cancer AJCC v7, Stage IV Gastric Cancer AJCC v7, Stage IV Lung Cancer AJCC v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IV Prostate Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7, Thyroid Gland Carcinoma
Register for Updates
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
NCT01772771
Recruiting
This study performs standardized testing of tumor tissue samples to learn which genes are mutated (have changed) in order to provide personalized cancer therapy options to cancer patients at MD Anderson. This may help doctors use testing information on tumors to identify clinical trials that may be most relevant to patients. Researchers may also use the information learned from this study to develop a database of the different kinds of mutations in cancer-related genes.
Gender:
ALL
Ages:
All
Trial Updated:
03/04/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Sarcoma, Glioma, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Melanoma
Register for Updates
A Checklist (Advanced Care Planning) for The Assessment of Mobility Needs in Patients With Sarcoma
NCT05835154
Recruiting
This trial tests how well the advanced care planning around mobility needs checklist tool works to assess future mobility needs in patients with sarcoma. Gathering information about sarcoma patients that have had surgery to either save or remove a limb may help doctors learn more about a patient's mobility needs. Using an advance care planning mobility needs assessment may help improve the quality of life in patients with sarcoma by helping them plan for their future mobility needs.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Metastatic Sarcoma, Sarcoma
Register for Updates
A Study of MGC026 in Participants With Advanced Solid Tumors
NCT06242470
Recruiting
The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort expansion portion of the study. Participants will receive MGC026 by intravenous (IV) infusion. The dose of MGC026 will be assigned at the time of enrollment. Participants may receive up to 35 treatments... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2025
Locations: The Angeles Clinic and Research Institute, Los Angeles, California +9 locations
Conditions: Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Sarcoma, Endometrial Cancer, Melanoma, Castration Resistant Prostatic Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Gastro-esophageal Cancer, Pancreas Cancer, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Platinum-resistant Ovarian Cancer
Register for Updates
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
NCT00005095
Recruiting
RATIONALE: To improve strategies for detection and prevention of early-stage disease. PURPOSE: This research study is collecting specimens and data to develop better methods for early detection and prevention of ovarian cancer among the high risk population and those who have the disease.
Gender:
FEMALE
Ages:
Between 18 years and 80 years
Trial Updated:
02/26/2025
Locations: Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois
Conditions: Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2), Ovarian Cancer, Sarcoma, Uterine Leiomyomata, Vaginal Cancer, Vulvar Cancer
Register for Updates
Registry of Sarcoma Patients Treated with Permanently Implantable LDR CivaSheet®
NCT04033081
Recruiting
This patient study will determine the safety and toxicity of a permanently implantable brachytherapy source - CivaSheet® - which is designed to deliver a therapeutic dose of low dose rate (LDR) radiation with polymer encased Palladium-103. CivaSheet will be implanted in sarcoma patients with disease presenting in the retroperitoneum, abdomen, pelvis and trunk.
Gender:
ALL
Ages:
All
Trial Updated:
02/24/2025
Locations: Rush University Cancer Center, Chicago, Illinois +1 locations
Conditions: Sarcoma
Register for Updates
Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma
NCT03886311
Recruiting
This is a Phase 2 study using talimogene laherparepvec, nivolumab, and trabectedin as first, second or third line therapy for advanced sarcoma, including desmoid tumor and chordoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Sarcoma Oncology Center, Santa Monica, California
Conditions: Sarcoma
Register for Updates
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
NCT06644755
Recruiting
This 2-part study will evaluate safety, tolerability, and clinical efficacy of DS-2243a as a treatment for participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts +1 locations
Conditions: Solid Tumors, Sarcoma
Register for Updates